Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.

Autor:	Hall MD; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Anderson JM; Office of the Director, National Institutes of Health, Bethesda, Maryland, USA., Anderson A; Pfizer Vaccine Research and Development, Pfizer, Pearl River, New York, USA., Baker D; University of Washington, Seattle, Washington, USA., Bradner J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Brimacombe KR; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Campbell EA; The Rockefeller University, New York, New York, USA., Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Carter K; Evotec, Lyon, France., Cherry S; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Chiang L; Evrys Bio, Doylestown, Pennsylvania, USA., Cihlar T; Gilead Sciences, Foster City, California, USA., de Wit E; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA., Denison M; Vanderbilt University, Nashville, Tennessee, USA., Disney M; Scripps Research, Jupiter, Florida, USA., Fletcher CV; University of Nebraska Medical Center, Omaha, Nebraska, USA., Ford-Scheimer SL; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Götte M; University of Alberta, Edmonton, Alberta, Canada., Grossman AC; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Hayden FG; University of Virginia, Charlottesville, Virginia, USA., Hazuda DJ; Merck & Co, Inc, Kenilworth, New Jersey, USA., Lanteri CA; Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Marston H; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Mesecar AD; Purdue University, West Lafayette, Indiana, USA., Moore S; University of Alabama at Birmingham, Birmingham, Alabama, USA., Nwankwo JO; 1910 Genetics, Inc, Cambridge, Massachusetts, USA., O'Rear J; US Food and Drug Administration, Silver Spring, Maryland, USA., Painter G; Emory University, Atlanta, Georgia, USA., Singh Saikatendu K; Takeda California, Inc, San Diego, California, USA., Schiffer CA; University of Massachusetts Medical School, Worcester, Massachusetts, USA., Sheahan TP; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA., Shi PY; University of Texas Medical Branch, Galveston, Texas, USA., Smyth HD; University of Texas at Austin, Austin, Texas, USA., Sofia MJ; Arbutus Biopharma, Inc, Warminster, Pennsylvania, USA., Weetall M; PTC Therapeutics, Inc, South Plainfield, New Jersey, USA., Weller SK; University of Connecticut School of Medicine, Farmington, Connecticut, USA., Whitley R; University of Alabama at Birmingham, Birmingham, Alabama, USA., Fauci AS; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Austin CP; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Collins FS; Office of the Director, National Institutes of Health, Bethesda, Maryland, USA., Conley AJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Davis MI; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2021 Jul 15; Vol. 224 (Supplement_1), pp. S1-S21.
DOI:	10.1093/infdis/jiab305
Abstrakt:	The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development. (Published by Oxford University Press for the Infectious Diseases Society of America 2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu